

CMRG RESEARCH TO REMISSION GRANT

Table of Contents

2021 – 2022 Application Key Dates	1
Program Description	2
Eligibility	2
Application Process.....	3
Study Concept General Information	4

2021 – 2022 Application Key Dates

Phase	Date
Call for Proposals	December 3 ,2021
Submission of study concept	December 30, 2021
Review Panel Meeting	January 19, 2022
Notification of Awards	January 24, 2022
Award Start Date	January 31, 2022



Program Description

The Canadian Myeloma Research Group (CMRG) is the only national non-profit research organization dedicated to conducting and supporting research in multiple myeloma and related disorders in Canada. The mission of CMRG is to cure multiple myeloma and improve the quality of life of people effected by it. Since its founding in 2016, CMRG, in partnership with its supporters, has invested millions of dollars for multiple myeloma research and continues to conduct and fund innovative research to advance breakthrough therapies.

CMRG supports research through the CMRG Research Grant program.

CMRG, supported by a research grant from Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc., will provide funding up to a maximum of \$150,000 for this grant in 2021. Funds for competitive applications will be awarded based on scientific merit, using a priority rating, and will include evaluation of ethical research. The Grant Review Committee (GRC) will review all qualifying applications and advise CMRG on awarding the grant. Young investigators as well as established ones are encouraged to submit applications.

The CMRG Research Grant is designed to provide funding to research that may lead to a significant change in the understanding, diagnosis, and/or treatment of multiple myeloma. Research utilizing CMRG database platform will be eligible to apply for this grant opportunity.

Eligibility

Investigators must demonstrate that their research environment is equipped and suitable for the proposed study; this includes demonstrated access to patient materials, where applicable. Collaboration between multiple investigators to strengthen the proposed research will be considered favorably but is not a requirement.

Applicants must be independent investigators affiliated with a non-profit Institution at the time funding commences and for the duration of the award. Applicants must have a faculty appointment at a Canadian university to qualify for funding. Applications from non-academic facilities are not eligible.

Applicants should hold a Ph.D., M.D., D.V.M. or equivalent degree.

Applications will require one Principal Investigator (PI) who is responsible for the preparation and submission of the proposal including the budget, the conduct of the research programs and adherence to all stipulations made by CMRG's Policies & Procedures document and the Grant Agreement, if funded and applicable.

The PI must be an independent investigator, which is defined as a clinician or scientist who has dedicated laboratory space and/or clinical practice, directly hires and supervises personnel (technicians,

graduate students, postdocs, and staff scientists) and makes all decisions concerning research activities and use of the grant funds. Postdoctoral fellows are not eligible to apply for a grant in this program.

A PI may only submit ONE application per application cycle and cannot serve as a PI OR Co-Principal Investigator on more than ONE application per cycle. A Co-Investigator (also known as Collaborator) CAN serve as Co-Investigator on more than one application. A Principal Investigator or Co-Principal Investigator can serve as a Collaborator on other Applications (See **Definitions** below).

The PI must be able to demonstrate a significant track record in multiple myeloma or related diseases research.

Definitions

Principal Investigator, Co-Principal Investigators, Co-Investigators, Collaborators, and Key Personnel:

- A Principal Investigator is the individual who is responsible for submitting the grant request. They CANNOT be named as a Principal Investigator or a Co-Principal Investigator on another application during the same application cycle.
 - A Principal Investigator can be listed as a Co-Investigator or a Collaborator on another application in the same cycle, without limit to the number of applications.
- The Co-Principal Investigator is responsible for developing the aims of the project.
- The Co-Investigator (who can also be referred to as Collaborator) is responsible for carrying out the aims of the project.
 - A Collaborator or Co-Investigator can be named on more than one application or funded grant, without limit.

Application Process

Applicants are asked to submit a study concept based on the guidelines outlined in the CMRG Grant Submission Document Guidelines, posted on the CMRG Grant Opportunities page of our website. After the submission deadline, the study proposals will be reviewed to ensure that they are aligned with program goals. Then, a CMRG appointed Grant Review Panel (GRP), will review the application. The GRP consist of a group of experts covering the science and medical aspects of the review. Final funding recommendations are approved by CMRG administration and the Board of Directors.

Only complete applications received by the submission deadline date will be considered.



Key Dates:

Phase	Date
Call for Proposals	December 3 ,2021
Submission of study concept	December 30, 2021
Review Panel Meeting	January 19, 2022
Notification of Awards	January 24, 2022
Award Start Date	January 31, 2022

General Information

The deadline to submit all Full Applications is Thursday December 30, 2021, at 4pm EST. The submission deadlines will be strictly enforced.

Qualified applications will be reviewed after the submission deadline by a CMRG appointed expert panel and will be evaluated for potential significance, novelty, innovation, and feasibility. Only applications related to the CMRG database will be considered for awarding grants this year.

Applications will be evaluated by CMRG. The GRP will select the proposal(s) to be funded based on scientific merit, responsiveness to program goals and budget availability. Final approval of funding will be made by the CMRG administration.

Applicants selected for funding will be notified by Monday January 24, 2022, of the funding decision. Please do not call or email CMRG to determine whether the Application has been received, when it will be reviewed or the results of the review. Funding decisions are relayed by email only and are not available by telephone.

All priority scores are confidential in that they are available to CMRG Board of Directors only. Feedback may only be provided for Applications discussed by the full review committee. Written critiques of the Application are not formally provided to Applicants.

Review Criteria to consider for Full Application

Significance

- Does this study address an important problem of clear relevance to Multiple Myeloma?
- What will be the effect of these studies on the field? Is the work high risk/high gain?
- Is the work related to Myeloma?

Approach

- Are the conceptual framework, design, methods, and analyses adequately developed and appropriate to the proposed work?
- Are potential problems identified and alternatives suggested?

Innovation

- Does the project employ novel concepts, approaches, or methods?
- Are the aims original and innovative?
- Does the project challenge existing paradigms, or develop new methodologies or technologies?

Investigator

- Is the project leader appropriately trained and suited to carry out the work?
- Is the work proposed appropriate to the experience of the investigator? Do not give a long history of the individual. Do not comment on publication record unless there is evidence of lack of productivity.

Environment

- Is the scientific environment adequate to contribute to the success of the project?
- Do the experiments take advantage of unique features of the scientific environment?